The Scottish Medicines Consortium Approves Gilead’s Zydelig® q (Idelalisib) for the Treatment of Follicular Lymphoma That Is Refractory to Two Prior Lines of Treatment in Adult Patients
Foster City, CA, 11 May 2015 – Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Scottish Medicines Consortium (SMC) has approved Zydelig…